Psychopharmacology and metabolic sindrome;Psicofármacos e síndroma metabólica

Acta Medica Portuguesa

Volumn 21, Issue 1-3, 2008, Pages 247-258

  Telles Correia, Diogo ^a   Guerreiro, Diogo F ^a   Coentre, Rui ^a   Gois C ^a   Figueira, Luísa ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DULOXETINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LEVOMEPROMAZINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THIORIDAZINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ARTERIAL PRESSURE; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSULIN RESISTANCE; MENTAL PATIENT; METABOLIC SYNDROME X; ORTHOSTATIC HYPOTENSION; PREVALENCE; PSYCHOPHARMACOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA;

DYSLIPIDEMIAS; FEMALE; GLUCOSE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PSYCHOTROPIC DRUGS;

EID: 51349132746     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9
2. KOH KK, HAN SH, QUON MJ: Inflammatory markers and the metabolic syndrome insights from therapeutic interventions. J Am Coll Cardiol 2005;46:1978
3. American Heart Association: Heart disease and stroke statistics: 2006 update. Disponível em: http://circ.ahajournals.org/cgi/content/full/113/ 6/e85. (Acedido em 30/1/2007)
4. LINDSAY RS, HOWARD BV: Cardiovascular risk associated with metabolic syndrome. Current Diabetes Report 2004;4:63
5. WEISS R, DZIURA J, BURGET TS et al: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362
6. ALBERTI KG, ZIMMET PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet Med 1998;15:539
7. National Cholesterol Education Program: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486
8. ALBERTI KG, ZIMMET P, SHAW J: The Metabolic Syndrome - a new worldwide definition. Lancet 2005;366:1059
9. MCEVOY JP, MEYER JM, GOFF DC et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsycotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
10. SACKS F: Metabolic Syndrome: Epidemiology and consequences. J Clin Psychiatry 2004;65(suppl 18):3-12
11. RAIMONDI L, ALFARANO C, PACINI A et al: Methylamine-dependent release of nitric oxide and dopamine in the CNS modulates food intake in fasting rats. Br J Pharmacol 2007;150:1003-10
12. WANG GJ, VOLKOW ND, LOGAN J et al: Brain dopamine and obesity. Lancet 2001;357:354-7
13. PARADA MA, PUIG DP, HERNANDZ L et al: Ventromedial hypothalamus vs. Lateral hypothalamic D2 satiety receptors in the body weight increase induced by systematic sulpride. Physiol Behav 1991;50:1161-5
14. TECOTT LH, SUN LM, AKANA SF et al: Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995;374:542-6
15. VICKERS SP, BENWELL KR, PORTER RH et al: Comparative effects of continuous infusion of MCPP,Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 2000;130:1305-14
16. EDER U, MANGWETH B, EBENBICHLER C et al: Association of olanzapine-induced weight gain with an increase body fat. Am J Psychiatry 2001;158:1719-22
17. WIRSHING DA, WIRSHING WC, KYSAR L et al: Novel antypsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363
18. KROEZE WK, HUFEISEIN SJ, POPADAK BA et al: H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 2003;35:220-5
19. MATSUI-SAKATA A, OHTANI H, SAWADA Y: Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20:368-378
20. FAVA M, JUDGE R, HOOG SL et al: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long term treatment. J Clin Psychiatry 200?;61:863-7
21. FAVA M: Weight gain and antidepressants. J Clin Psychiatry 2000;61(suppl):37-41
22. KRAUS T, HAACK M, SCHULD A. et al: Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002;35:220-5
23. CROFT H, HOUSER TL, JAMERSON BD et al: Effect on body weight of bupropion sustained-release in patients with major depression. Depress Anxiety 2000; 11:58-65
24. EDWARDS JG, ANDERSON I: Systemic review and guide to selection of selective serotonin re-uptake inhibitors. Drugs 1999;57:507-533
25. MCGUIRK J, SILVERSTONE T: The effect of 5-HT re-uptake inhibitor fluoxetina on food intake and body weight in healthy male subjects. Int J Obes 1990;14:361-371
26. SHEKELLE PG, MORTON SC, MAGLIONE MA et al: Pharmacological and Surgical Treatment of Obesity. Evidence Report/ Technology Assessment No.103. Rockville, MD, Agency for Healthcare Research and Quality 2004
27. MICHELSON D, AMSTERDAM JD, QUITKIN FM et al: Changes in weight during 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-6
28. KECK PE, MCELROY SL: Bipolar disorder, obesity and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-35
29. ALLISON DB, FONTAINEKR, HEO M et al: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220.
30. LIBERMAN JA, STROUP TS, MCEVOY JP et al: Effectiveness of ansipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
31. WIRSHING DA: Schizophrenia and obesity: Impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl 18):13-26
32. BAPTISTA T, ZARATE J, JOOBER R et al: Drug induced weight gain, an impediment to successful farmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5:279-299
33. LIBERMAN JA: Dopamine partial agonists: a new class of antipsychotic drugs in patients with chronic schizophrenia. CNS Drugs 2004;18:251-267
34. REAVEN GM: Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrionol Metab Clin North Am 2005;34:49-62
35. HOUSEKNECHT K: Diabetogenic effects of some atypical antipsycotics: rapid, whole body insulin resistance following a single dose. Diabetologia 2005;48(suppl):A212
36. JOHNSON DE, YAMAZAKI H, WARD KM et al: Diabetes 2005;54:1552-8
37. CIECHANOWSKI PS, KATON WJ, RUSSO JE, HIRSH IB: The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 2003;25(4):246-252
38. ISOTANI H, KAMEOKA K: Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999;22(5):862-3
39. WEIDEN PJ, LOEBEL A, YANG et al: Course of weight and metabolic benefits 1 year after switching to ziprasidone. Abstract presented at the annual meeting of the American Psychiatric Association. New York May 2004
40. BERGMAN RN, ADER M: Atypical antipsychotics and glucose homeostasis.J Clin Psychiatry 2005;66:504-514
41. SCHEEN AJ, DE HERT MA: Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007; 33(3):169-715
42. HOUSEKNECHT KL, ROBERTSON AS, JOHNSON DE, ROLLEMA H: Clozapine and olanzapine, but not ziprasidone, cause acute insulin resistance in normal rats. Biol Psychiatry 2005;57:128S
43. HENDERSON DC et al: Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006;67(5):789-797
44. RETTENBACHER MA et al: Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol 2007;21(4):400-4
45. TEITELBAUM M: Severe And Moderate Hipertriglyceridemia Secondary to Citalopram and Fluoxetine. Psychosomatics 2000;41:5
46. TEITELBAUM M, GARDENS PB: Severe hypertrigliceridemia secondary to venlafaxine and fluoxetine. Psychosomatics 2001;42:3
47. HELDENBERG D, HAREL S, HOLTZMAN M, LEVTOW O, TAMIR I: The effect of chronic anticonvulsivant therapy on serum lipids and lipoproteins in epileptic children. Neurol 1983;33:510-3
48. CALANDRE EP, RODRIGUEZ-LOPEZ C, BLAZQUEZ A, CANO D: FERUM lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or Phenobarbital. Acta Neurol Scand 1991;83(4):250-3
49. ISOJARVI JI, RATTYA J, MYLLYLA VV, KNIP M, KOIVUNEN R, PAKARINEN AJ: Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43(4):446-451
50. SASAKI J, KUMAGAE G, SATA T, KURAMITSU M, ARAKAWA K: Decrease concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis 1984;51(2-3):163-9
51. HAUPT DW, NEWCOMER JW: Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002;53:925-933
52. RICHARD IH: Severe mental illness, antipsychotic drugs and the metabolic syndrome. Br Diabetes Vasc Dis 2006;6:199-204
53. BAYES DL, COUMEL P, LECLERQ JF: Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159
54. FUSTER V, BADIMON L, BADIMON JJ et al: The pathogenesisof coronary artery disease and the acute coronary syndromes, part 1. N Engl J Med 1992;326:242-250
55. ROOSE SP: Depression, Anxiety, and the Cardiovascular System: The psychiatrist's perspective. Psychiatry 2001;62(suppl 8):19-22
56. ROOSE SP, LAGHRISSI-THODE F, KENNEDY JS et al: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279(4):287-291
57. THASE ME: Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59(10):502-8
58. JOHNSON EM, WHYTE E, MULSANT BH et al: Cardiovascular changes associated with venlafaxine in the treatment of latelife depression. Am J Geriatr Psychiatry 2006;14(9):796-802
59. National Institute for Clinical Excellence: Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE 2004
60. THASE ME, TRAN PV, WILTSE C: Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25(2):132-40
61. STAHL S, ZIVKOV M, REIMITZ PE et al: Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand 1997;391(Suppl):22-30
62. BOYD IW: Hypertension with moclobemide. Lancet 1995;346:1498
63. PENTTILA J, SYVALAHTI E, HINKKA S et al: The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001;154(4):343-9
64. NEWCOMER JW: Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67(Suppl 9):25-30
65. MITCHELL JE, MACKENZIE TB: Cardiac effects of lithium therapy in man: a review. J Clin Psychiatry 1982;43(2):47-51
66. ABIDI S, BHASKARA SM: Chlorpromazine to clozapine - antipsychotic adverse effects and the clinician's dilemma. Can J Psychiatry 2003;48(11):749-55
67. NEWCOMER JW, HAUPT DW: The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51(8):480-91
68. FEINSTEIN RE: Cardiovascular effects of novel antipsychotic medications. Heart Dis 2002;4(3):84-90
69. Expert Group: Schizophrenia and Diabetes: Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 2004; 47 (Suppl): S112-S114
70. LAMBERT TJ, CHAPMAN LH: Consensus Working Group: diabetes, psychotic disorders, and antipsychotic therapy: a consensus statement. Med Aust 2004;181:544-548
71. MARDER SR, ESSOK SM, MILLER AL, ET AL. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
72. BERMUDES RA. Metabolic syndrome: five risk factors guide therapy, easy-to-use clinical values tell when to intervene. Current Psychiatry 2005;4:73-88